Neuromodulation News and Research

RSS

Sorin Group third quarter revenues decrease 2.1% to €171.4 million

Sorin Group: Revenues of €171.4 million, a 2.1% decline (-4.9% as reported) over the same period last year.

29 Oct 2011

external Trigeminal Nerve Stimulation pediatric clinical trial for ADHD receives NeuroSigma funding

NeuroSigma, Inc., a Los Angeles-based medical technology company, announced today that it has signed a contract with the University of California, Los Angeles (UCLA) to fund a Phase I pediatric clinical trial to study the use of non-invasive, external Trigeminal Nerve Stimulation (TNS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

24 Oct 2011

St. Jude Medical third quarter net sales increase 12% to $1.383 billion

St. Jude Medical, Inc. today reported sales and net earnings for the third quarter ended October 1, 2011.

19 Oct 2011

EMKinetics initiates TranStim therapy pivotal trial for urge incontinence, overactive bladder

EMKinetics, Inc. announced today initiation of the TranStim Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder.

14 Oct 2011

Enrollment begins in Boston Scientific's vagal nerve stimulation trial for heart failure

Boston Scientific Corporation has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.

30 Sep 2011

Ultrasonic neuromodulation can be quickly applied in neurocritical care situations

The discovery that low-intensity, pulsed ultrasound can be used to noninvasively stimulate intact brain circuits holds promise for engineering rapid-response medical devices.

9 Sep 2011

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received the industry's first and only regulatory approval for the use of an implanted neurostimulation device for patients with intractable chronic migraine.

7 Sep 2011

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX for injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

25 Aug 2011

Medtronic first quarter global revenue increases 7% to $4.049 billion

Medtronic, Inc. today announced financial results for its first quarter of fiscal year 2012, which ended July 29, 2011.

From Medtronic 23 Aug 2011

Boston Scientific introduces NLI online resource center for healthcare providers

Boston Scientific Corporation has launched its Neuromodulation Learning Institute (NLI), a clinical education program and online resource center for healthcare providers to enhance their knowledge and awareness of spinal cord stimulation (SCS) technology, procedures and techniques.

11 Aug 2011

St. Jude Medical second quarter net sales increase 10% to $1.447 billion

St. Jude Medical, Inc. today reported sales and net earnings for the second quarter ended July 2, 2011.

20 Jul 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

Combined pediatric neuroscience programs at Barrow Neurological Institute

St. Joseph's Hospital and Medical Center and Phoenix Children's Hospital jointly announced this week their pediatric neuroscience programs are combining under the newly formed Barrow Neurological Institute at Phoenix Children's Hospital.

24 Jun 2011

Barrow Neurological Institute announces Phoenix Children’s Hospital as new pediatric affiliate

St. Joseph’s Hospital and Medical Center and Phoenix Children’s Hospital jointly announced today their pediatric neuroscience programs are combining under the newly formed Barrow Neurological Institute at Phoenix Children’s Hospital.

22 Jun 2011

CerebralRx launches FitNeS vagus nerve stimulation system for treating epilepsy

CerebralRx, a newly formed spin-off of implantable neuromodulation systems developer BioControl Medical, has announced market entry with the launch of its FitNeS vagus nerve stimulation system.

14 Jun 2011

Revance closes $45 million financing

Revance Therapeutics, Inc. today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital.

10 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

UK's NICE issues guidance on PTNS treatment for faecal incontinence

Uroplasty, Inc., announced today that the United Kingdom's National Institute for Health and Clinical Excellence issued guidance on percutaneous tibial nerve stimulation for the treatment of faecal incontinence.

31 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011